Is Lidocaine + Tetracaine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 3 valid registrations of Lidocaine + Tetracaine, including NEURODERM (70,70 mg/g,mg/g, Cream, SAR 39.60); Pliaglis 15 gram Cream (7,7 %,%, Cream, SAR 76.90); Pliaglis 30 gram Cream (7,7 %,%, Cream, SAR 139.15).

Is Lidocaine + Tetracaine approved by the US FDA?

Drugs@FDA lists 2 application product lines for Lidocaine + Tetracaine, including PLIAGLIS (Prescription); SYNERA (Discontinued).

Active substances

Lidocaine + Tetracaine

SFDA 3
US FDA 2
Health Canada 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
NEURODERM	70,70 mg/g,mg/g	Cream · Topical	1 Tube	SAR 39.60	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
Pliaglis 15 gram Cream	7,7 %,%	Cream · Topical	1 Tube	SAR 76.90	NCE · Prescription	Crescita Therapeutics, Inc	Valid
Pliaglis 30 gram Cream	7,7 %,%	Cream · Topical	1 Tube	SAR 139.15	NCE · Prescription	Crescita Therapeutics, Inc	Valid

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
PLIAGLIS	7%;7%	cream · topical	CRESCITA THERAP	Prescription	29 Jun 2006
SYNERA	70MG;70MG	patch · topical	GALEN SPECIALTY	Discontinued	23 Jun 2005

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
PLIAGLIS	02398028	7 %; 7 %	CREAM · TOPICAL	SCIENCES DE LA PEAU CRESCITA INC. / CRESCITA SKIN SCIENCES INC.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.